cagrisema phase 3 results 2025 semaglutide cagrilintide obesity Novo Nordisk shares plunge after drug trial disappoints Novo's CagriSema loses phase 3
Novo's CagriSema loses phase 3 obesity battle against Zepbound Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine Novo Nordisk's CagriSema outperforms Ozempic in Phase III trial CagriSema in Adults With or Without Diabetes REDEFINE 1 & 2 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly 20.4% weight loss (non diabetic) & 13.7% (T2D) What are the side effects of Cagrisema? Common symptoms
Pay in 4 interest-free payments of $6.30 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4




